Epigenetic Reprogramming (Yamanaka Factors / OSK)

Epigenetic reprogramming represents not a supplement but a biological intervention category that is transitioning from theoretical breakthrough to clinical trial reality. The foundation is Shinya Yamanaka's 2006 Nobel Prize-winning discovery that four transcription factors (Oct4, Sox2, Klf4, c-Myc — collectively OSKM) can reprogram adult cells back to an induced pluripotent stem cell (iPSC) state. The challenge for longevity applications: full reprogramming erases cellular identity and risks teratoma formation. The paradigm shift came with partial reprogramming: brief, transient expression of OSKM (or the safer OSK subset, excluding the oncogenic c-Myc) that resets the epigenetic clock without inducing full pluripotency. David Sinclair's lab at Harvard demonstrated in 2020 that OSK expression in retinal ganglion cells reversed epigenetic age and restored visual function in aged and damaged mice — the first demonstration that mammalian tissue aging could be reversed in vivo. Subsequent work has extended this to muscle, kidney, brain, and liver tissues. Preclinical evidence published in 2025 (PMC12610414) demonstrates that partial OSKM reprogramming resets the epigenome without inducing pluripotency across multiple tissue types, with gene expression profiles reverting to youthful patterns. The mechanistic target is epigenetic drift — the progressive, stochastic accumulation of methylation errors at CpG sites that constitutes one of the most robustly measured aging hallmarks (the DNA methylation clocks developed by Horvath and others directly measure this). The clinical translation is accelerating. Life Biosciences has been developing ER-100, a partial epigenetic reprogramming therapeutic targeting clinic entry in Q1 2026. Altos Labs (backed by over $3 billion in funding) is actively researching mesenchymal drift reversal and whole-body epigenetic reprogramming approaches. These are not consumer supplements — they are sophisticated gene therapy and small-molecule approaches requiring clinical delivery. For the biohacker community, the immediate relevance is conceptual and forward-looking: epigenetic reprogramming is the mechanism that upstream interventions like AKG, NMN, and senolytics are attempting to influence indirectly. The compounds that preserve epigenetic fidelity or reduce drift rate — AKG as TET cofactor, NAD+ for PARP-mediated repair, senolytics for SASP-driven epigenetic disruption — can be understood as supporting the substrate that reprogramming seeks to reset.